Adjuvant radiotherapy after extrapleural pneumonectomy for mesothelioma. Prospective analysis of a multi-institutional series.

BACKGROUND AND PURPOSE: To evaluate survival, locoregional control and toxicity in a series of 56 mesothelioma patients treated from May 2005 to May 2010 with post-operative radiotherapy after extrapleural pneumonectomy (EPP) in three Italian Institutions (Brescia, Florence, and Modena). MATERIAL AND METHODS: Fifty-six patients treated with adjuvant radiotherapy (RT) after EPP were analyzed. Four patients were treated with 3DCRT, 50 with IMRT and two with helical tomotherapy. Forty-five to 50 Gy in 25 fractions were given to the affected hemithorax and to ipsilateral mediastinum, with a simultaneous integrated boost to the sites of microscopically involved margins up to 60 Gy in 20/56 cases. RESULTS: Three year locoregional control (LRC), distant metastasis free (DMF), disease free (DF), disease specific (DSS) and overall survival (OS) rates are 90%, 66%, 57%, 62%, and 60%, respectively. CONCLUSION: Postoperative RT with modern techniques is an effective method to obtain excellent local control and cure rates in mesothelioma patients submitted to EPP.

Accelerated partial breast irradiation with IMRT: new technical approach and interim analysis of acute toxicity in a phase III randomized clinical trial.

PURPOSE: To evaluate with a randomized clinical trial the possibility of treating the index quadrant with external intensity-modulated radiotherapy (IMRT) in a selected group of patients with early-stage breast cancer and to analyze the acute toxicity. METHODS AND MATERIALS: From September 2005, a randomized Phase III clinical trial has been conducted to compare conventional (tangential field) fractionated whole breast treatment (Arm A) with accelerated partial breast irradiation plus intensity-modulated radiotherapy (Arm B). For intensity-modulated radiotherapy, the clinical target volume was drawn with a uniform 1-cm margin around the surgical clips in three dimensions. The ipsilateral and contralateral breast, ipsilateral and contralateral lung, heart, and spinal cord were contoured as organs at risk. All the regions of interest were contoured according to the International Commission on Radiation Units and Measurements reports 50 and 62 recommendations. RESULTS: In September 2008, 259 patients were randomized and treated. The mean clinical target volume in Arm B was 44 cm(3) and the mean planning target volume was 123 cm(3). The mean value of the ratio between the planning target volume and the ipsilateral breast volume was 21%. The rate of Grade 1 and Grade 2 acute skin toxicity was 22% and 19% in Arm A (Radiation Therapy Oncology Group scale), respectively. The tolerance in Arm B was excellent with only 5% Grade 1 and 0.8% Grade 2 acute skin toxicity. The planning constraints were fully satisfied in most patients. In a very few cases, this was not possible because of very unfavorable anatomy. Quality assurance procedures were performed according to our internal quality assurance protocol, with excellent results. CONCLUSION: In the present preliminary analysis, we have demonstrated that accelerated partial breast irradiation is feasible, with very low acute toxicity.

Accelerated intensity-modulated external radiotherapy as a new technical approach to treat the index quadrant after conserving surgery in early breast cancer: a preliminary study.

PURPOSE: We present a novel technical approach to treat the index quadrant after conserving surgery in patients with early breast cancer and study its clinical feasibility. METHODS AND MATERIAL: Patients selected for the study, after breast conserving surgery with histologically verified breast carcinoma, signed a full informed consent to intensity-modulated external radiotherapy of the partial breast. Treatment was performed with the 6 MV beam from one of the Elekta Precise LINAC units installed in our Department. The prescribed dose was 30 Gy in 5 fractions in 10 days. RESULTS: Acute toxicity was minimal. No skin changes were noted during treatment or during the first 6 months after radiotherapy treatment. CONCLUSIONS: Accelerated partial breast irradiation using intensity-modulated external radiotherapy is technically feasible. We think the approach will give good results in terms of local control, toxicity and quality of life, at the same time sparing resources for the patient and health care system.

Verification of IMRT fields by film dosimetry.

In intensity modulated radiation therapy (IMRT) the aim of an accurate conformal dose distribution is obtained through a complex process. This ranges from the calculation of the optimal distribution of fluence by the treatment planning system (TPS), to the dose delivery through a multilamellar collimator (MLC), with several segments per beam in the step and shoot approach. The above-mentioned consideration makes mandatory an accurate dosimetric verification of the IM beams. A high resolution and integrating dosimeter, like the radiographic film, permits one to simultaneously measure the dose in a matrix of points, providing a good means of obtaining dose distributions. The intrinsic limitation of film dosimetry is the sensitivity dependence on the field size and on the measurement depth. However, the introduction of a scattered radiation filter permits the use of a single calibration curve for all field sizes and measurement depths. In this paper the quality control procedure developed for dosimetric verification of IMRT technique is reported. In particular a system of film dosimetry for the verification of a 6 MV photon beam has been implemented, with the introduction of the scattered radiation filter in the clinical practice that permits one to achieve an absolute dose determination with a global uncertainty within 3.4% (1 s.d.). The film has been calibrated to be used both in perpendicular and parallel configurations. The work also includes the characterization of the Elekta MLC. Ionimetric independent detectors have been used to check single point doses. The film dosimetry procedure has been applied to compare the measured absolute dose distributions with the ones calculated by the TPS, both for test and clinical plans. The agreement, quantified by the gamma index that seldom reaches the 1.5 value, is satisfying considering that the comparison is performed between absolute doses.